Novo Nordisk A/S

Novo Nordisk A/S (https://www.novonordisk.com/) is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Nicio pagină nu întrunește aceste criterii.

• Cum reactioneaza BVB-ul? - 07 noiembrie 2024
• Constructiile rezidentiale in scadere - 25 septembrie 2024
• Novo Nordisk A/S
• BNR reduce dobanda de referinta - 08 august 2024
• Aproape 100,000 de investitori activi - 04 iulie 2024
• Comertul cu amanuntul, in primele 4 luni din an - 07 iunie 2024
• PIB-ul Romaniei in 2023 - 11 martie 2024
• SIF-urile, inceput slab la bursa - 13 februarie 2024
• Preturile productiei industriale, in termeni anuali, au scazut - 05 septembrie 2023
• BNR a mentinut rata de politica monetara - 09 august 2023